Research outputs

@article{Zarranz-Ventura2025,

title = {Brolucizumab clinical and safety outcomes in a neovascular age-related macular degeneration national database: Fight Retinal Blindness Spain (FRB Spain)},

author = {Javier Zarranz-Ventura and Sonia Marias-Perez and Ruben Martin-Pinardel and Manel Fernandez-Bonet and Begona Pina-Marin and Estefania Cobos and Carmen Antia Rodriguez-Fernandez and Alba Parrado-Carrillo and Isaac Alarcon-Valero and Carles Barnes and Esther Cilveti and Julia Aramburu-Claveria and Francisco J Ascaso-Puyuelo and Pilar Calvo and Maria Pilar Ruiz-Del-Tiempo and Gabriela Susanna-Gonzalez and Marc Figueras-Roca and Ricardo P Casaroli-Marano and Carolina Bernal-Morales},

doi = {10.1038/s41433-025-03871-6},

issn = {1476-5454},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {Eye},

volume = {39},

number = {12},

pages = {2407–2414},

keywords = {Eye, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Zarranz-Ventura2025b,

title = {Treatment intervals with first-generation anti-vascular endothelial growth factor drugs: evaluating the unmet need in a real-world neovascular age-related macular degeneration national database},

author = {Javier Zarranz-Ventura and Gonzaga Garay-Aramburu and Pilar Calvo and Miguel Angel Zapata and Carolina Arruabarrena and Pablo Arnaiz and Paula Garcia-Lunar and Laura Sararols-Ramsay},

doi = {10.1038/s41433-025-03996-8},

issn = {1476-5454},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {Eye},

volume = {39},

number = {18},

pages = {3306–3313},

keywords = {Eye, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Puzo2024,

title = {Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study},

author = {Martín Puzo and Pilar Calvo-Perez and Francisco Bartol-Puyal and Jorge Sanchez-Monroy and Ruben Martin-Pinardel and Alba Parrado-Carrillo and Aina Moll-Udina and Carolina Bernal-Morales and Laura Sanchez-Vela and Laura Sararols-Ramsay and Gonzaga Garay-Aramburu and Carolina Arruabarrena and José García-Arumí and Maximino Abraldes and José María Ruiz-Moreno and Xavier Valldeperas and Daniel Velázquez-Villoria and José Juan Escobar-Barranco and Roberto Gallego-Pinazo and Marta S. Figueroa and Marc Figueras-Roca and Daniel Barthelmes and Mark C. Gillies and Ricardo P. Casaroli-Marano and Javier Zarranz-Ventura and},

doi = {10.1038/s41433-024-03322-8},

issn = {1476-5454},

year  = {2024},

date = {2024-12-00},

journal = {Eye},

volume = {38},

number = {18},

pages = {3450–3458},

publisher = {Springer Science and Business Media LLC},

keywords = {Eye, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Kandel2023,

title = {Comparison of standard versus accelerated corneal collagen cross-linking for keratoconus: 5-year outcomes from the Save Sight Keratoconus Registry},

author = {Himal Kandel and Marco Abbondanza and Aanchal Gupta and Richard Mills and Adam S. Watson and Constantinos Petsoglou and Yves Kerdraon and Stephanie L. Watson},

doi = {10.1038/s41433-023-02641-6},

issn = {1476-5454},

year  = {2024},

date = {2024-01-00},

journal = {Eye},

volume = {38},

number = {1},

pages = {95–102},

publisher = {Springer Science and Business Media LLC},

abstract = {Objective To compare long-term effectiveness of Standard (UV intensity: 3 mW/cm 2 , duration: 30 min) vs Accelerated (UV intensity: 9 mW/cm 2 , duration: 10 min) corneal cross-linking (CXL) for stabilising keratoconus. Methods Data for this observational study were captured through a web-based registry system from the routine clinical practice (15 sites across Australia, New Zealand and Italy). The outcomes were compared using mixed-effects regression models. A total of 100 eyes (75 patients) who had standard CXL and 76 eyes (66 patients) who had accelerated CXL, with a follow-up visit at five-year post-CXL were included. Results Both CXL protocols were effective and safe in stabilising keratoconus and improving outcomes. The adjusted mean changes (95% CI) in outcomes were better in standard CXL than in accelerated CXL [visual acuity gain, 10.2 (7.9–12.5) vs 4.9 (1.6–8.2) logMAR letters; pinhole visual acuity 5.7 (3.5–7.8) vs 0.2 (−2.2 to 2.5) logMAR letters; Kmax −1.8 (−4.3 to 0.6) vs 1.2 (−1.5 to 3.9)D; K2 −0.9 (–2.2 to 0.3) vs 0.1 (−1.3 to 1.6)D; MCT –3.0 (−13.7 to 7.7) vs −11.8 (−23.9 to 0.4) µm ( p values for visual acuity, pinhole visual acuity, Kmax: <0.05; for K2 and MCT: >0.05)]. The frequency of adverse events at the 5-year follow-up visit was low in both groups [standard, 5 (5%; haze 3; scarring 1, epithelial defect 1) and accelerated 3 (3.9%; haze 2, scarring 1)]. Conclusions Both standard and accelerated CXL were safe and effective procedures for stabilising keratoconus in the long term. The standard CXL resulted in greater improvements in visual acuity and keratometry.},

keywords = {Eye, Fight Corneal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Bhandari2022,

title = {Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion},

author = {Sanjeeb Bhandari and Vuong Nguyen and Adrian Hunt and Pierre-Henry Gabrielle and Francesco Viola and Hemal Mehta and Les Manning and David Squirrell and Jennifer Arnold and Ian L. McAllister and Daniel Barthelmes and Mark Gillies},

doi = {10.1038/s41433-022-02075-6},

issn = {1476-5454},

year  = {2023},

date = {2023-04-00},

journal = {Eye},

volume = {37},

number = {6},

pages = {1145–1154},

publisher = {Springer Science and Business Media LLC},

abstract = {Objectives To identify whether the outcomes of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in routine clinical practice have changed over time. Methods We analysed 12-month outcomes in treatment-naïve eyes that started aflibercept or ranibizumab for nAMD (3802 eyes), DMO (975 eyes), Branch RVO (BRVO, 357 eyes), Central RVO (CRVO, 371 eyes) and Hemi-RVO (HRVO, 54 eyes) from 2015 and 2019 tracked in the prospectively designed observational Fight Retinal Blindness! Registry. Results The mean VA change at 12-month for each year between 2015 and 2019 remained stable or otherwise showed no discernible trends over time in eyes with nAMD (+3.3 to +6 letters), DMO (+3.6 to +6.7 letters) and RVO (+10.3 to +11.7 letters for BRVO, +5.9 to +17.7 letters for CRVO and 10.2 to 20.7 letters for HRVO). The median number of VEGF-inhibitor injections in eyes that completed 12-month follow-up also remained stable at 8–9 for nAMD, 6–7 for DMO, 7–9 for RVO. Fewer eyes (<one-fourth) that started treatment between 2015 and 2018 and more eyes starting in 2019 did not complete 12-month’s follow-up visit. The mean VA in non-completers at their last visit was higher than that of their baseline visit. Conclusions Treatment patterns and outcomes for nAMD, DMO and RVO in routine clinical practice have stabilised over the past 5 years at levels inferior to those reported by the pivotal phase 3 studies. A conscious effort to treat these conditions more intensively, or with longer lasting agents, would likely improve outcomes further in our patients.},

keywords = {Eye, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Teo2022,

title = {Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration},

author = {Kelvin Y. C. Teo and Vuong Nguyen and Louise O’Toole and Vincent Daien and Jorge Sanchez-Monroy and Federico Ricci and Theodorus Leonardus Ponsioen and Helena Brosa Morros and Chui Ming Gemmy Cheung and Jennifer J. Arnold and Daniel Barthelmes and Mark C. Gillies},

doi = {10.1038/s41433-022-01957-z},

issn = {1476-5454},

year  = {2023},

date = {2023-02-00},

journal = {Eye},

volume = {37},

number = {3},

pages = {467–473},

publisher = {Springer Science and Business Media LLC},

keywords = {Eye, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Bhandari2021,

title = {Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry},

author = {Sanjeeb Bhandari and David Squirrell and Vuong Nguyen and Nancy Wang and Jane M. Wells and Terence Tan and Rachel Barnes and Richard Barry and Daniel Barthelmes and Mark Gillies},

doi = {10.1038/s41433-021-01509-x},

issn = {1476-5454},

year  = {2022},

date = {2022-03-00},

journal = {Eye},

volume = {36},

number = {3},

pages = {594–602},

publisher = {Springer Science and Business Media LLC},

keywords = {Eye, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}

@article{Teo2020,

title = {Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence},

author = {Kelvin Yi Chong Teo and Vuong Nguyen and Daniel Barthelmes and Jennifer J. Arnold and Mark C. Gillies and Chui Ming Gemmy Cheung},

doi = {10.1038/s41433-020-01315-x},

issn = {1476-5454},

year  = {2021},

date = {2021-10-00},

journal = {Eye},

volume = {35},

number = {10},

pages = {2793–2801},

publisher = {Springer Science and Business Media LLC},

keywords = {Eye, Fight Retinal Blindness},

pubstate = {published},

tppubtype = {article}

}